重要的消息有哪些 12月23日（周二）申购提示 4．中国人民银行决定实施一次性信用修复政策。对于2020年1月1日至2025年12月31日期间，单笔金额 不超过10000元人民币的个人逾期信息，个人于2026年3月31日（含）前足额偿还逾期债务的，金融信用 信息基础数据库将不予展示。其中：（一）个人于2025年11月30日（含）前足额偿还逾期债务的，金融 信用信息基础数据库自2026年1月1日起不予展示相关逾期信息；（二）个人于2025年12月1日至2026年3 月31日之间足额偿还逾期债务的，金融信用信息基础数据库于次月月底前不予展示相关逾期信息。 1．近日，中共中央办公厅、国务院办公厅印发了《关于做好2026年元旦春节期间有关工作的通知》。 《通知》提出，确保市场供应平稳有序。全力做好煤电油气生产、运输保障，确保民生用能保供稳价， 保障群众温暖过冬。落实粮食安全党政同责和"菜篮子"市长负责制，强化市场监测预警，发挥交通物流 保通保畅工作机制作用，保障粮油肉蛋奶果蔬等生活必需品供应充足、价格平稳。扩大优质商品和服务 供给，创新多元消费场景，激发假期消费潜力。强化餐饮服务食品安全和市场销售食用农产品质量安全 ...

证券研究报告 2025 年 12 月 21 日 湘财证券研究所 行业研究 医疗耗材行业周报 湖南牵头 29 省高频电刀集采启动 相关研究： | 1. 《第五批耗材国采即将落地执 | | | --- | --- | | 行》 | 2025.02.18 | | 2.《年报披露密集期，耗材板块关 | | | 注创新与业绩修复》 | 2025.04.01 | 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -2 -9 -9 绝对收益 -1 -7 7 -50.00% 0.00% 50.00% 沪深300 医疗耗材 注：相对收益与沪深 300 相比 分析师：聂孟依 证书编号：S0500524040001 Tel：(8621) 50299667 Email：nmy06967@xcsc.com 地址：上海市浦东新区银城路 88 号 中国人寿金融中心 10 楼 核心要点： ❑ 医疗耗材板块上周上涨 2.29% 根据 wind，上周，医药生物报收 8269.04 点，下跌 0.14%，涨幅排名位列 申万一级行业第 22 位，跑赢沪深 300 指数 0.14 个百分点；医疗服务报收 637 ...

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...

来源：新浪证券-红岸工作室 12月19日，采纳股份跌0.28%，成交额4770.88万元，换手率2.26%，总市值34.28亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 该股筹码平均交易成本为27.84元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近支撑位 27.70，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 采纳股份所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：融资融券 ...

12月19日，赛诺医疗盘中上涨2.00%，截至09:54，报17.85元/股，成交3045.69万元，换手率0.41%，总 市值74.26亿元。 赛诺医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、小盘、QFII 持股、融资融券、专精特新等。 截至9月30日，赛诺医疗股东户数2.94万，较上期增加164.74%；人均流通股14170股，较上期减少 62.23%。2025年1月-9月，赛诺医疗实现营业收入3.64亿元，同比增长14.24%；归母净利润2111.80万 元，同比增长293.46%。 分红方面，赛诺医疗A股上市后累计派现4100.00万元。近三年，累计派现0.00元。 责任编辑：小浪快报 资金流向方面，主力资金净流入5.67万元，大单买入402.49万元，占比13.22%，卖出396.82万元，占比 13.03%。 赛诺医疗今年以来股价涨82.89%，近5个交易日跌0.22%，近20日跌0.56%，近60日跌39.08%。 今年以来赛诺医疗已经7次登上龙虎榜，最近一次登上龙虎榜为10月29日，当日龙虎榜净买入-5123.31 万元；买入总计2.04亿元 ，占总成交额比1 ...

Core Viewpoint - The company, Canar Medical, has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, particularly in its overseas revenue which constitutes a significant portion of its business [1][3]. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue components of Canar Medical include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 28, the number of shareholders in Canar Medical is 8,801, a decrease of 2.05% from the previous period, while the average circulating shares per person increased by 2.09% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86%. The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On December 18, Canar Medical's stock price increased by 0.43%, with a trading volume of 46.28 million yuan and a turnover rate of 2.17%, resulting in a total market capitalization of 3.44 billion yuan [1]. - The company has been experiencing a net outflow of funds, with a net outflow of 1.05 million yuan on the day of the report, indicating a lack of strong market support [4][5]. Group 4: Technical Analysis - The average trading cost of Canar Medical's shares is 27.83 yuan, with the stock price currently near a support level of 27.75 yuan. There are indications of accumulation, but the strength of this accumulation is weak [6].

来源：新浪证券-红岸工作室 12月18日，中红医疗涨0.46%，成交额6745.59万元，换手率1.31%，总市值56.10亿元。 异动分析 核污染防治+宠物经济+医疗器械概念+人民币贬值受益+国企改革 1、2024年度可持续发展（ESG）报告：提出"六防"核辐射防护手套的技术需求，与桂林理工大学联合 研发团队进行为期一年的科技攻关，对标先进企业核辐射防护手套产品的结构及性能，研发出具有化学 防护层、白色警示层、核辐射防护层和穿戴内层的多层核辐射防护手套的关键材料体系和成型工艺。 2、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席，其中迈德瑞纳宠物泵，备受瞩目。展会上， 中红医疗旗下迈德瑞纳 UniFusion SP50 Vet 及 UniFusion VP50 Vet 兽用输注泵备受关注，两款产品具备 IP34 防水设计和双 CPU 架构，能提供多种输液模式及微量模式最大流速设置，兼顾安全与多功能性。 兽医现场体验后表示，输注泵操作便捷，可切换电池或电源运行，能提供精准、安全、易用的输液方 案，适配多种场景 ...

Group 1: Market Overview - Major tech stocks experienced declines, with Tesla and Broadcom dropping over 4%, Google down over 3%, and Meta and Apple falling over 1% [1] - Energy and precious metals sectors saw gains, with ConocoPhillips rising over 4% and ExxonMobil and BP increasing over 2% [1] Group 2: Oracle's Challenges - Oracle faced significant setbacks in its ambitious AI infrastructure expansion plan, as its largest data center partner, Blue Owl Capital, decided to withdraw support for a $10 billion data center project [1] - Despite the setback, Oracle stated that negotiations for the project are proceeding as planned and that the overall progress is on track, with the deal not including Blue Owl Capital [1] - Analysts suggest that this incident highlights potential risks in the funding chain for AI infrastructure as private credit markets tighten [1] Group 3: Nvidia's Market Impact - Nvidia shares fell by 3.81%, resulting in a market value loss of $164.8 billion (approximately 1160.8 billion RMB) [2][3] - The decline is attributed to competitive pressures and a broader downturn in the sector [3] Group 4: Medline's IPO Success - Medline Inc. had a successful IPO, with shares rising 41.38% on the first day to $41, after pricing at $29, raising $6.26 billion [4][5] - The company specializes in manufacturing and distributing medical supplies, including gloves and surgical gowns, and has secured commitments from cornerstone investors [4]

④ 【华纳据称本周将拒绝派拉蒙收购要约】12月16日，据媒体援引知情人士透露，华纳兄弟探索（简称华纳）计划拒绝派拉蒙天舞上周提出的收购要 约，主要原因是对派拉蒙天舞的融资安排和其他交易条款存在担忧。华纳董事会经过审议后认为，公司与奈飞的现有协议在价值、确定性和条款方面都优 于派拉蒙天舞的提案。截至发稿，奈飞上涨1.83%。 每经记者｜岳楚鹏 每经编辑｜段炼 兰素英 ① 【三大期指齐涨】截至发稿，道指期货涨0.19%、标普500指数期货涨0.30%、纳指期货涨0.34%。 ② 【纳斯达克将迎来年内全球最大IPO】美东时间12月17日晚，纳斯达克交易所将迎来全球今年最大IPO Medline，股票代码"MDLN"。该IPO发行规模经 上调后，最终定价锁定在推介区间高位。具体来看，该公司将以每股29美元发行2.16亿股股票，拟融资约62.6亿美元，定价对应的公司估值约为390亿美 元。Medline现有股东涵盖黑石集团、凯雷集团及弗里德曼（Hellman & Friedman）三大私募巨头。早在2021年，这三家机构就以340亿美元联合收购 Medline多数股权，成为史上规模最大的杠杆收购之一。Medline由米 ...

Core Viewpoint - Nasdaq is set to launch "around-the-clock trading" services starting in 2026 to meet the growing demand from investors for continuous trading in the U.S. stock market [3][4]. Group 1: Around-the-Clock Trading - Nasdaq plans to extend daily trading hours from 16 hours to 23 hours, operating five days a week, with a new schedule that includes a daytime session from 4:00 AM to 8:00 PM and a night session from 9:00 PM to 4:00 AM [5]. - The initiative aims to enhance the ability of investors, particularly those outside the U.S., to respond quickly to market dynamics occurring outside regular trading hours [6]. - Other exchanges, including the New York Stock Exchange and the Chicago Board Options Exchange, have announced similar plans for around-the-clock trading [4]. Group 2: Medline IPO - Medline, the largest IPO of the year, is set to debut on Nasdaq with an offering price of $29 per share for 216 million shares, aiming to raise approximately $6.26 billion, which values the company at around $39 billion [7]. - The company has reported revenues of $20.6 billion and a net profit of $977 million for the past nine months, showing an increase from $18.7 billion in revenue and $911 million in net profit in the same period last year [7]. - Major investors in Medline's IPO include Blackstone, Carlyle Group, and Hellman & Friedman, with cornerstone investors committing up to $2.35 billion [8].